Disease response and patient-reported outcomes among initiators of ixekizumab

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

“…These findings are consistent with those reported in other real-world studies for ixekizumab, which showed improvements in BSA involvement, dermatology-specific HRQL, and disease severity over time with ixekizumab treatment [ 17 – 19 ].…”

“…A similar trend was seen in the study by Leonardi and colleagues [ 18 ], where the percent of patients with clear or minimal involvement improved from 19.6% at baseline to 84% (from figure) at week 24. Patients in this study and a study by Shahriari and colleagues [ 19 ] demonstrated similar magnitudes of improvement in the proportion of patients with BSA involvement of ≤ 3%, from 43.8% and 18.4% at baseline, respectively, to 84.6% and 72.1% at week 24; and mean BSA scores improved 74.8% and 77.5% in these studies, respectively. The consistency in findings across real-world studies is particularly impressive given that BSA involvement in our study was measured by patients via the PREPI, rather than by physicians as in the other studies [ 18 , 19 ].…”

“…Similar findings for overall disease severity also were noted; the percent of patients with scores of 0 (clear) or 1 on global assessment scales was 13.3%, 34.0%, and 69.6% at baseline and weeks 4 and 24 for our study (patient-rated; 6-point scale) and 7.2%, 58.8%, and 76% (from figure) at the same timepoints in Leonardi and colleagues’ work [ 18 ] (physician-rated; 7-point scale). In another study, the percent of patients with scores of 0 (clear) or 1 on a 5-point, physician-rated global assessment scale was 7.4% and 50.7% at baseline and week 24, respectively [ 19 ]. Similar magnitudes of improvement from baseline to week 24 also were seen for itch and pain using an 11-point NRS in our study and a 0 to 100 visual analog scale in another study [ 19 ].…”

“…In another study, the percent of patients with scores of 0 (clear) or 1 on a 5-point, physician-rated global assessment scale was 7.4% and 50.7% at baseline and week 24, respectively [ 19 ]. Similar magnitudes of improvement from baseline to week 24 also were seen for itch and pain using an 11-point NRS in our study and a 0 to 100 visual analog scale in another study [ 19 ]. Though the findings are generally consistent, comparisons may be impacted by differences in the scale structures.…”

Treatment Persistence of Ixekizumab in Adults with Moderate-to-Severe Plaque Psoriasis Participating in the Canadian Patient Support Program

“…PASI score ranges from 0 to 72, with higher scores indicating greater severity [ 29 ]. BSA is reported as percent involvement on a scale of 0–100% and characterized as mild (0% to < 3%), moderate (3–10%), or severe (> 10%) on the basis of the amount of affected body surface area [ 30 ]. The DLQI is a 10-item questionnaire that covers six domains including daily activities, leisure, symptoms and feelings, personal relationships, work and school, and treatment, and inquires about experiences in the last week [ 31 ].…”